Back to search results

Observational Study of Xiidra for Ocular Discomfort in Glaucoma Patients

This study is looking at how well an FDA-approved eye drop called Xiidra (lifitegrast ophthalmic solution) 5% works for people with glaucoma who experience eye discomfort. This discomfort can be caused by other eye drops they use for glaucoma. You might be able to join if you are currently using glaucoma eye drops and have symptoms of eye discomfort, and your doctor is prescribing Xiidra as part of your usual care. The study will measure changes in your eye dryness, corneal staining (a way to check the surface of your eye), and overall eye discomfort using a questionnaire over 12 weeks. The current recruitment status is unclear.

Study design
This is an observational study involving about 75 participants. It will look at how patients respond to Xiidra when it's prescribed as part of their standard care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks to measure changes in their eye discomfort and other symptoms.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04354545

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Recruiting
Not specifiedAll AgesObservational
University of California, Los Angeles
~75 participants
Updated 2026-03-13 on ClinicalTrials.gov
What's tested:Xiidra (Lifitegrast ophthalmic solution) 5%

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline to week 12 in corneal fluorescein staining score
Measured over From baseline to Week 12
+2 more outcomes measured

Conditions

Glaucoma
Ocular Surface Disease

Explore related trials

GlaucomaOcular Surface Disease, CTCAE

Where it's being run

1 sites across 1 states
California1

Who to contact

Benjamin B Bert, MD
[email protected]
626-817-4701
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Currently using one or more topical glaucoma antihypertensives
Self-described symptoms of ocular surface discomfort
Xiidra is being prescribed as part of the subject's standard care

Exclusion

History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
current use of topical cyclosporine
current use of topical steroids
incisional ocular surgery within 6 months

What this trial measures

  • Change from baseline to week 12 in corneal fluorescein staining scoreFrom baseline to Week 12

    Change in corneal fluorescein staining score

  • Change from baseline to week 12 in eye dryness score (EDS)From baseline to Week 12

    Change in eye dryness score (EDS)

  • Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire scoreFrom baseline to Week 12

    Change in ocular surface disease index (OSDI) questionnaire score